Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer

European Journal of Cancer Prevention

Volumn 15, Issue 4, 2006, Pages 347-352

  Maucort Boulch, Delphine ^a,b   Roy, Pascal ^a  

^a LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Breast cancer; Chemoprevention; Modelization; Mortality; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EUROPEAN AMERICAN; EXPERIENCE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL; TIME; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; COMPUTER SIMULATION; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM INVASIVENESS; PLACEBOS; PULMONARY EMBOLISM; SURVIVAL ANALYSIS; TAMOXIFEN; TIME;

EID: 33745931928     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200608000-00008     Document Type: Article

References (25)

1. Assikis VJ, Jordan VC (1995). Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 49:241-257.
2. Brenner H, Hakulinen T (2002). Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 20:826-832.
3. Cogliano V, Grosse Y, Straif B, Secretan B, El Ghissassi F (2005). Carcinogenicity of combined oestrogen-progestaen contraceptives and menopausal treatment. Lancet Oncol 6:552-553.
4. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817-824.
5. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
6. Early Breast Cancer Trialists' Collaborative Group (1988). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692.
7. Esteve J, Benhamou E, Raymond L (1994). Statistical methods in cancer research. Descriptive epidemiology. Lyons, France: IARC Press.
8. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, et al. (1986). Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4:459-471.
9. Fisher B, Redmond C (1991). New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 83:1278-1280.
10. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537.
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
12. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, III (1999). Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159: 445-453.
13. International Agency for research on Cancer (2005). IARC monographs on the evaluation of carcinogenic risks to humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. 91. 2005. Lyons, France: International Agency for research on Cancer Press.
14. Kramer R, Brown P (2004). Should tamoxifen be used in breast cancer prevention? Drug Safety 27:979-989.
15. Lasset C, Bonadona V, Mignotte H, Bremond A (2001). Tamoxifen and risk of endometrial cancer. Lancet 357:66-67.
16. Meier CR, Jick H (1998). Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612.
17. Mortimer JE, Urban JH (2003). Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. Oncology (Williston Park) 17:652-659.
18. Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618.
19. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101.
20. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J (1996). Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737.
21. Ragaz J, Coldman A (1998). Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16:2018-2024.
22. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. (1991). Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299-1306.
23. Schairer C, Mink PJ, Carroll L, Devesa SS (2004). Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311-1321.
24. Swerdlow AJ, Jones ME (2005). Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97: 375-384.
25. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. (1998). Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97.